{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:06:28Z","timestamp":1784700388104,"version":"3.55.0"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>T cell-engaging antibody constructs (TCEs) have emerged as a potent modality to treat cancer and autoimmune diseases. Twelve TCEs have been approved by the FDA and EMA for the treatment of hematological malignancies or solid tumors. Despite the varying designs and binding properties, they all lead to robust single-agent efficacy and approvals in refractory or relapsed leukemia, lymphomas, multiple myeloma (MM), small cell lung cancer, EpCAM-expressing cancers or uveal melanoma. Where comparisons can be deduced, TCEs appear to achieve response rates like those obtained with CAR-T cell therapies. Given the success of the first generation of TCEs, considerable attempts are underway to further improve upon this modality. With the goal of expanding TCEs into other malignant and autoimmune indications, and to further enhance efficacy and improve safety, a multitude of novel TCEs are currently in preclinical and clinical development. Here we review the current approaches to developing next-generation TCEs that can widen the therapeutic index, address heterogeneous target expression, and thereby potentially improve efficacy and safety.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1885909","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:41Z","timestamp":1784699561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation T cell engagers for cancer and autoimmune diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Jennifer S.","family":"Michaelson","sequence":"first","affiliation":[{"name":"Cullinan Therapeutics, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Henry","sequence":"additional","affiliation":[{"name":"Cullinan Therapeutics, Inc.","place":["Cambridge, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Sauer","sequence":"additional","affiliation":[{"name":"Cullinan Therapeutics, Inc.","place":["Cambridge, MA, United States"]},{"name":"Department of Immunology and Microbiology, The Scripps Research Institute","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Baeuerle","sequence":"additional","affiliation":[{"name":"Cullinan Therapeutics, Inc.","place":["Cambridge, MA, United States"]},{"name":"Institute for Immunology, Biomedical Center, Ludwig Maximilian University of Munich","place":["Martinsried-Planegg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20251652","article-title":"T cell engagers emerge as a compelling therapeutic modality","volume":"223","author":"Baeuerle","year":"2026","journal-title":"J Exp Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03069-5","article-title":"B cell depletion in autoimmune disease: in vivo CAR-T or T cell engagers","volume":"44","author":"Senior","year":"2026","journal-title":"Nat Biotechnol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1665838","article-title":"Current landscape of T-cell engagers in early-phase clinical development in solid cancers","volume":"16","author":"Spinazzola","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"Geraud","year":"2024","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0060043","article-title":"Surface-anchored monomeric agonist pMHCs alone trigger TCR with high sensitivity","volume":"6","author":"Ma","year":"2008","journal-title":"PloS Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"107","author":"Lutterbuese","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0179","article-title":"FDA supplemental approval: Blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia","volume":"23","author":"Pulte","year":"2018","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18071088","article-title":"Precision-engineered CD3 T-cell engagers for solid tumours: Conditional activation, microenvironment modulation, and clinical translation","volume":"18","author":"Zeyaullah","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454747","article-title":"Cutting-edge approaches to B-cell depletion in autoimmune diseases","volume":"15","author":"Robinson","year":"2024","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41408-024-01179-4","article-title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","volume":"14","author":"Jabbour","year":"2024","journal-title":"Blood Cancer J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: Achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2026.2613548","article-title":"The making of multispecific immunoglobulins - a clinical perspective","volume":"18","author":"Brinkmann","year":"2026","journal-title":"MAbs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007398","article-title":"CLN-978, a novel half-life extended CD19\/CD3\/HSA-specific T cell-engaging antibody construct with potent activity against B-cell Malignancies with low CD19 expression","volume":"11","author":"Meetze","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B19","article-title":"Development pipeline: janux","volume-title":"Janux.","year":"2026"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004336","article-title":"Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186","volume":"10","author":"Dettling","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-sitc2025.0961","article-title":"961 CX-908, a PROBODY\u00ae T cell engager targeting CDH3 and CD3, induces tumor regressions and improves the therapeutic window in preclinical studies","volume":"13","author":"Scolan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B22","unstructured":"Pipeline: Werewolf Therapeutics\n          \n          \n          \n          2026"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-sitc2025.0972","article-title":"972 Masked T cell engagers designed to drive potent synthetic anti-tumor immunity with favorable tolerability","volume":"13","author":"Guzman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B24","article-title":"FORM 10-K, ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934","volume-title":"United States Securities and Exchange Commission: Harpoon Therapeutics, Inc.","year":"2022"},{"key":"B25","article-title":"Revitope\u2014third-generation T cell engager immunotherapies","volume-title":"Wwwnaturecom\/Biopharmdeal.","author":"Clement","year":"2021"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1182\/blood-2023-189058","article-title":"NVG-222: A first-in-class autoregulating half-life extended ROR1xCD3 T cell engager heralding a new class of safer drugs","volume":"142","author":"Granger","year":"2023","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030027","article-title":"Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models","volume":"147","author":"Pillarisetti","year":"2026","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-nd06","article-title":"Abstract ND06: AMG 305, a dual targeting BiTE\u00aemolecule with selective activity for solid tumors that co-express CDH3 and MSLN","volume":"83","author":"Pham","year":"2023","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-23-0692","article-title":"The CD33xCD123xCD70 multispecific CD3-engaging DARPin MP0533 induces selective T cell-mediated killing of AML leukemic stem cells","volume":"12","author":"Bianchi","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-23-0638","article-title":"Engineering CD3\/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small-cell lung cancer","volume":"12","author":"Mikami","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2024-198745","article-title":"Pre-clinical evaluation of AZD5492, a novel CD8-guided T cell engager, for B-non Hodgkin lymphoma indications","volume":"144","author":"Lawrence","year":"2024","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2025.2522088","article-title":"The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: Is it really that simple","volume":"20","author":"Abdelmotaleb","year":"2025","journal-title":"Expert Opin Drug Discov"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2023-174668","article-title":"Double step-up dosing (2SUD) regimen mitigates severe ICANS and CRS while maintaining high efficacy in subjects with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) treated with AZD0486, a novel CD19xCD3 T-cell engager (TCE): Updated safety and efficacy data from the ongoing first-in-human (FIH) phase 1 trial","volume":"142","author":"Gaballa","year":"2023","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1182\/blood-2024-193681","article-title":"Evaluation of AZD0486, a novel CD19xCD3 T-cell engager, in relapsed\/refractory diffuse large B-cell lymphoma in an ongoing first-in-human phase 1 study: High complete responses seen in CAR-T-naive and CAR-T-exposed patients","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"key":"B38","article-title":"Amgen stops trial of Teneobio cancer candidate, taking $650M BiTE out of earnings: FIERCE Biotech","volume-title":"Fierce Biotech.","author":"Taylor","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE(R)) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2025.09.22.677496","DOI":"10.1101\/2025.09.22.677496","article-title":"Potentiating CAR-T bystander killing by enhanced Fas\/FasL signaling mitigates antigen escape in heterogeneous tumors","author":"Lin","year":"2025","journal-title":"bioRxiv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.07.009","article-title":"Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen, in patients with advanced gastrointestinal adenocarcinomas","volume":"15","author":"Pishvaian","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: Results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2018-0451","article-title":"The multifaceted roles of tumor-associated proteases and harnessing their activity for prodrug activation","volume":"400","author":"Vasiljeva","year":"2019","journal-title":"Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: Regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"A1376","DOI":"10.1136\/jitc-2022-sitc2022.1325","article-title":"Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T cell engager for treatment of metastatic castration-resistant prostate cancer","volume":"10","author":"DiRaimondo","year":"2022","journal-title":"BMJ"},{"key":"B50","doi-asserted-by":"publisher","first-page":"B04","DOI":"10.1158\/2326-6074.tumimm22-b04","article-title":"Abstract B04: Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors","volume":"10","author":"DiRaimondo","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-1457","article-title":"Probody therapeutics: An emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0964","article-title":"964 Development of conditional T cell engagers (INDUCER\u2122 molecules) with a highly effective masking approach to reduce dose-limiting cytokine release and off-target peripheral toxicity. Regular and Young Investigator Award Abstracts","volume":"13","author":"Cafarelli","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2021-933","article-title":"Abstract 933: ProTriTAC is a modular and robust T cell engager prodrug platform with therapeutic index expansion observed across multiple tumor targets","volume":"81","author":"Lin","year":"2021","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1792130","article-title":"COBRA: A highly potent conditionally active T cell engager engineered for the treatment of solid tumors","volume":"12","author":"Panchal","year":"2020","journal-title":"MAbs"},{"key":"B55","unstructured":"Clinicaltrials.Gov\n          \n          \n          \n          2026"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2026.44.7_suppl.17","article-title":"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC)","volume":"44","author":"De Bono","year":"2026","journal-title":"J Clin Oncol"},{"key":"B57","unstructured":"Pipeline: Vir Biotechnology\n          \n          \n          \n          2026"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S492","DOI":"10.1016\/j.annonc.2023.09.1897","article-title":"711TiP a phase I\/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR \u00d7 CD3\u03f5 COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors","volume":"34","author":"Weickhardt","year":"2023","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-1825","article-title":"Abstract 1825: QSP modeling to inform dose and regimen selection for TAK-280: A bi-specific antibody","volume":"86","author":"Dey","year":"2026","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps2684","article-title":"A phase 1\/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3\u03f5 conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors","volume":"42","author":"Richardson","year":"2024","journal-title":"J Clin Oncol"},{"key":"B61","unstructured":"Cytomx Pipeline: Cytomx Therapeutics\n          \n          \n          \n          2026"},{"key":"B62","article-title":"CytomX therapeutics announces 2024 financial results and provides business update: globeNewswire","volume-title":"Globenewswire.","year":"2025"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-2483","article-title":"A Probody T cell-engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res"},{"key":"B64","unstructured":"Astellas walks away from $1.6B biobucks T-cell engager pact with CytomX after 6 years: FIERCE Biotech\n          \n          \n            \n              Maddox\n              W\n            \n          \n          \n          2026"},{"key":"B65","unstructured":"Unlocking the potential of immuno-oncology therapies: Xilio Therapeutics [Corporate Investor Presentation\n          \n          \n          \n          2026"},{"key":"B66","unstructured":"Pipeline: Xilio Therapeutics\n          \n          \n          \n          2026"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-2927","article-title":"Abstract 2927: ITGB6 ProTriTAC\u2122, a protease-activated T cell engager prodrug targeting Integrin-\u03b26 for the treatment of solid tumors","volume":"83","author":"Lin","year":"2023","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-2928","article-title":"Abstract 2928: TROP2 ProTriTAC\u2122, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors","volume":"83","author":"Rocha","year":"2023","journal-title":"Cancer Res"},{"key":"B69","unstructured":"Powered for precision: revitope oncology\n          \n          \n          \n          2026"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2125","article-title":"Encouraging long-term efficacy and safety from first-in-human phase 1 study of time-limited NVG-111 in relapsed\/refractory CLL and MCL","volume":"146","author":"Townsend","year":"2025","journal-title":"Blood"},{"key":"B71","unstructured":"Pipeline: Novalgen\n          \n          \n          \n          2026"},{"key":"B72","article-title":"Vir biotechnology corporate overview presentation vir biotechnology website: vir biotechnology","volume-title":"Vir Biotechnology.","year":"2026"},{"key":"B73","article-title":"Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC: Vir Biotechnology, Inc","volume-title":"Vir Biotechnology, Inc.","year":"2025"},{"key":"B74","article-title":"Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC: Janux Therapeutics Investor Relations","volume-title":"Janux Therapeutics Investor Relations.","year":"2025"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052514","article-title":"The tumor proteolytic landscape: a challenging frontier in cancer diagnosis and therapy","volume":"22","author":"Vizovisek","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15227","article-title":"Protease-activated prodrugs: strategies, challenges, and future directions","volume":"287","author":"Poreba","year":"2020","journal-title":"FEBS J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1523693","article-title":"Prodrug-based bispecific antibodies for cancer therapy: advances and future directions","volume":"16","author":"Ai","year":"2025","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00172","article-title":"Bempegaldesleukin plus nivolumab in untreated advanced melanoma: the open-label, phase III PIVOT IO 001 trial results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"B79","article-title":"Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review","volume":"49","author":"Vaupel","year":"1989","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-024-01178-7","article-title":"Severely polarized extracellular acidity around tumour cells","volume":"8","author":"Feng","year":"2024","journal-title":"Nat BioMed Eng"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1039\/c8ra02095g","article-title":"Manipulating extracellular tumour pH: an effective target for cancer therapy","volume":"8","author":"Hao","year":"2018","journal-title":"RSC Adv"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.068981","article-title":"Tumor pH and its measurement","volume":"51","author":"Zhang","year":"2010","journal-title":"J Nucl Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2026.2658902","article-title":"Engineering of acidic pH-responsive anti-CD3 binding antibodies","volume":"18","author":"La Sala","year":"2026","journal-title":"MAbs"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2020606118","article-title":"Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches","volume":"118","author":"Chang","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.503","article-title":"486P Preliminary results from a first-in-human phase I study of a dual-conditionally binding EpCAM x CD3 bispecific T-cell engager, BA3182, in pts with treatment refractory metastatic adenocarcinoma","volume":"36","author":"Starodub","year":"2025","journal-title":"Ann Oncol"},{"key":"B86","doi-asserted-by":"crossref","unstructured":"BioAtla reports fourth quarter and full year 2025 financial results and business highlights [Press Release\n          \n          \n          \n          2026","DOI":"10.1016\/j.fopow.2025.03.013"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-6340","article-title":"Abstract 6340: Novel conditionally active tetravalent B7-H3 x CD3 T-cell engagers targeting solid tumors","volume":"84","author":"Cugnetti","year":"2024","journal-title":"Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-5392","article-title":"Abstract 5392: Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202","volume":"86","author":"Roberts","year":"2026","journal-title":"Cancer Res"},{"key":"B89","unstructured":"Amberstone Webpage\n          \n          \n          \n          2026"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-6014","article-title":"Abstract 6014: A new generation of tumor microenvironment activated therapeutic (T-MATE) targeting solid tumors","volume":"85","author":"Ma","year":"2025","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-2644","article-title":"Abstract 2644: Enhancing safety to unlock efficacy: A novel class of conditionally-activated T cell engagers for solid tumors","volume":"86","author":"Segaliny","year":"2026","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105385","article-title":"36O First-in-human phase I study of a dual-conditionally active biologic (CAB) EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, in patients with treatment refractory metastatic adenocarcinoma","volume":"10","author":"Goldstein","year":"2025","journal-title":"ESMO Open"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.06.029","article-title":"Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4(+) myasthenia gravis","volume":"33","author":"Schreiber","year":"2025","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200109)31:9<2829::aid-immu2829>3.0.co;2-u","article-title":"Biased activation of human T lymphocytes due to low extracellular pH is antagonized by B7\/CD28 costimulation","volume":"31","author":"Bosticardo","year":"2001","journal-title":"Eur J Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1038\/s41467-020-17756-7","article-title":"T-cells produce acidic niches in lymph nodes to suppress their own effector functions","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B96","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-019-0393-7","article-title":"Evidence-based guidelines for controlling pH in mammalian live-cell culture systems","volume":"2","author":"Michl","year":"2019","journal-title":"Commun Biol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2023.08.008","article-title":"pH sensing at the intersection of tissue homeostasis and inflammation","volume":"44","author":"Hajjar","year":"2023","journal-title":"Trends Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002599","article-title":"Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase","volume":"3","author":"Pellegatti","year":"2008","journal-title":"PloS One"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 purinergic signalling in the tumour microenvironment","volume":"18","author":"Di Virgilio","year":"2018","journal-title":"Nat Rev"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/science.106.2742.66","article-title":"Comparison of the \u03b2-glucuronidase activity of normal, tumor, and lymph node tissues of surgical patients","volume":"106","author":"Fishman","year":"1947","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.108.2805.355","article-title":"The presence of high beta-glucuronidase activity in cancer tissue","volume":"169","author":"Fishman","year":"1947","journal-title":"J Biol Chem"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0328","article-title":"Antibody to CD137 activated by extracellular adenosine triphosphate is tumor selective and broadly effective in vivo without systemic immune activation","volume":"11","author":"Kamata-Sakurai","year":"2021","journal-title":"Cancer Discov"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013397","article-title":"ROSE12, a novel anti-CTLA-4 FcgammaRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation","volume":"14","author":"Hayashi","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1021\/ml100039h","article-title":"Expanded utility of the \u03b2-glucuronide linker: ADCs that deliver phenolic cytotoxic agents","volume":"1","author":"Jeffrey","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14020396","article-title":"Fibroblast-like synoviocytes as key regulators of homeostasis and inflammation in the joint microenvironment of inflammatory arthritis","volume":"14","author":"Lee","year":"2026","journal-title":"Biomedicines"},{"key":"B107","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/art.1780090106","article-title":"Measurement of synovial fluid pH in normal and arthritic knees","volume":"9","author":"Cummings","year":"1966","journal-title":"Arthritis Rheum"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood-2024-199211","article-title":"MP0533 (CD33 x CD123 x CD70 x CD3), a tetra-specific CD3-engaging darpin for the treatment of patients with relapsed\/refractory AML or MDS\/AML: Results of an ongoing phase 1\/2a study","volume":"144","author":"Jongen-Lavrencic","year":"2024","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"CT147","DOI":"10.1158\/1538-7445.am2025-ct147","article-title":"Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed\/refractory multiple myeloma patients","volume":"85","author":"Garton","year":"2025","journal-title":"Cancer Res"},{"key":"B110","article-title":"AbbVie and Ichnos Glenmark Innovation (IGI) announce exclusive global licensing agreement for ISB 2001, a first-in-class CD38\u00d7BCMA\u00d7CD3 trispecific antibody","volume-title":"Abbview Webpage.","year":"2025"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results","volume":"43","author":"van de Donk","year":"2025","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-2135","article-title":"Abstract 2135: QLS4131, a proprietary T cell engager targeting both BCMA and GPRC5D for the treatment of multiple myeloma","volume":"85","author":"Yang","year":"2025","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3381.2","DOI":"10.1182\/blood-2024-200737","article-title":"A phase I first-in-human, open-label trial to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SIM0500, a humanized GPRC5D-BCMA-CD3 trispecific antibody, in participants with relapsed or refractory multiple myeloma","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"key":"B114","article-title":"AbbVie and Simcere Zaiming announce partnership to develop a novel trispecific antibody candidate in multiple myeloma","volume-title":"Abbview, Inc.","year":"2025"},{"key":"B115","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-140154","article-title":"Preclinical study of a novel tri-specific anti-CD3\/CD19\/CD20 T cell-engaging antibody as a potentially better treatment for NHL","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"B116","first-page":"1","article-title":"GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline","volume-title":"Gsk Webpage.","year":"2024"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-5400","article-title":"Abstract 5400: QLS2313, a CD79b\/CD20 tri-specific T cell engager with dual-targeting strategy developed as a new therapeutics for the treatment of DLBCL","volume":"86","author":"Lu","year":"2026","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309697","article-title":"Targeting dual immune checkpoints PD-L1 and HLA-G by trispecific T cell engager for treating heterogeneous lung cancer","volume":"11","author":"Lin","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-261","article-title":"Abstract 261: A mRNA-encoded trispecific CD19xBCMAxCD3 T cell engager to treat cancer and autoimmunity","volume":"86","author":"Cao","year":"2026","journal-title":"Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1038\/s41467-019-13196-0","article-title":"On-target restoration of a split T cell-engaging antibody for precision immunotherapy","volume":"10","author":"Banaszek","year":"2019","journal-title":"Nat Commun"},{"key":"B122","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/978-3-030-55378-4_19","article-title":"Evolving treatment strategies for EGFRex20ins-mutated NSCLC: a comprehensive review of Amivantamab's role and future directions","volume":"19","author":"Pereira","year":"2025","journal-title":"Ecancermedicalscience"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2531223","article-title":"Innovative strategies for T cell engagers for cancer immunotherapy","volume":"17","author":"Bergamaschi","year":"2025","journal-title":"MAbs"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5989","article-title":"Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy","volume":"11","author":"Claus","year":"2019","journal-title":"Sci Transl Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abp9229","article-title":"A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors","volume":"15","author":"Melero","year":"2023","journal-title":"Sci Transl Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3581","article-title":"A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors","volume":"31","author":"de Bono","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04380-z","article-title":"Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial","author":"Melero","year":"2026","journal-title":"Nat Med"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-2125","article-title":"Abstract 2125: The trispecific T cell engager platform enhances T cell function and therapeutic efficacy via integrated 4-1BB nanobody co-stimulation","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1182\/blood-2024-204614","article-title":"First-in-human phase 1 study of SAR442257 in patients with relapsed\/refractory multiple myeloma and non-Hodgkin lymphoma","volume":"144","author":"Schjesvold","year":"2024","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-5389","article-title":"Abstract 5389: CC312, a novel CD19\/CD3\/CD28 tri-specific T cell engager, leads to rapid and deep B-cell depletion and has broad potential for development in autoimmune diseases","volume":"86","author":"Sun","year":"2026","journal-title":"Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-3513","article-title":"Abstract 3513: CC312, a trispecific CD19-targeting co-stimulatory T cell engager, for the treatment of B cell Malignancies and autoimmune diseases","volume":"85","author":"Huang","year":"2025","journal-title":"Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"TPS2668","DOI":"10.1891\/9780826155146.0036","article-title":"GNC-038, a tetra-specific antibody, in patients with R\/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2022-168904","article-title":"PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell Malignancies","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2018-3752","article-title":"Abstract 3752: Preclinical pharmacology of MP0310: A 4-1BB\/FAP bispecific DARPin drug candidate promoting tumor-restricted T-cell costimulation","volume":"78","author":"Link","year":"2018","journal-title":"Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","first-page":"TPS2682","DOI":"10.1200\/jco.2026.44.16_suppl.tps2682","article-title":"Eiu-104101: A first-in-human phase 1a\/1b study of EVOLVE104, a trispecific CD3\u00d7CD2\u00d7ULBP2\/5\/6 T-cell engager, in advanced urothelial and squamous cell carcinomas","volume":"44","author":"Fiorino","year":"2026","journal-title":"J Clin Oncol"},{"key":"B139","unstructured":"Marengo presents initial phase 2 results demonstrating broad single-agent activity of Invikafusp Alfa across multiple PD-1-refractory or -resistant solid tumors as a late-breaking oral presentation at ESMO 2025 PR Newswire: PR Newswire\n          \n          \n          \n          2025"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2008.11.014","article-title":"Mode of cytotoxic action of T cell-engaging BiTE antibody MT110","volume":"214","author":"Haas","year":"2009","journal-title":"Immunobiology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-sitc2025.1316","article-title":"1316 initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR \u03b2-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1\/2 trial","volume":"13","author":"Marabelle","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"PS4-06-28","DOI":"10.1158\/1557-3265.sabcs25-ps4-06-28","article-title":"Abstract PS4-06-28: Initial clinical and pharmacology results from START-002: A phase 1b\/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T cell agonist, in combination with sacituzumab govitecan in patients with mTNBC or HR+\/HER2- mBC","volume":"32","author":"Isakoff","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"CT205","DOI":"10.1158\/1538-7445.am2025-ct205","article-title":"Abstract CT205: Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1\/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors","volume":"85","author":"Sullivan","year":"2025","journal-title":"Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"PS5-09-16","DOI":"10.1158\/1557-3265.sabcs25-ps5-09-16","article-title":"PS5-09-16: A phase 1b\/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+\/HER2- MBC (START-002 trial)","volume":"32","author":"Isakoff","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/b978-0-323-56738-1.00008-7","article-title":"Discovery of JNJ-89853413, a first-in-class CD33xV\u03b42 T-cell engager for the treatment of acute myeloid leukemia","volume":"144","author":"El Ashkar","year":"2024","journal-title":"Blood"},{"key":"B146","unstructured":"Australian New Zealand Clinical Trials Registry\n          \n          \n          \n          2026"},{"key":"B147","article-title":"LAVA Therapeutics enters agreement to be acquired by XOMA Royalty Corporation and announces discontinuation of LAVA-1266 development","volume-title":"Quiver Quantitative.","year":"2025"},{"key":"B148","doi-asserted-by":"publisher","first-page":"TPS2672","DOI":"10.1200\/jco.2024.42.16_suppl.tps2672","article-title":"Phase I\/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC)","volume":"42","author":"Mehra","year":"2024","journal-title":"J Clin Oncol"},{"key":"B149","article-title":"LAVA reports third quarter 2024 financial results and announces pipeline reprioritization and cash runway extension into 2027","volume-title":"Globenewswire","year":"2024"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166851","article-title":"Lava-051, a novel bispecific gamma-delta T-cell engager (Gammabody), in relapsed\/refractory MM and CLL: Pharmacodynamic and early clinical data","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vgamma9Vdelta2 T cell-mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci Transl Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2022-ct188","article-title":"Abstract CT188: ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION trial","volume":"82","author":"Champiat","year":"2022","journal-title":"Cancer Res"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-ct179","article-title":"Abstract CT179: First-in-human study of ICT01, an anti-BTN3A activating monoclonal antibody in combination with low dose IL-2 in patients with advanced solid tumors (EVICTION-2 study)","volume":"83","author":"de Bono","year":"2023","journal-title":"Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-sitc2025.1307","article-title":"1307 ICT01, a \u03b39\u03b42 T-cell-activating mAb, in combination with pembrolizumab elicits deep and durable responses in second-line patients with primary refractory melanoma: Results from EVICTION study","volume":"13","author":"Champiat","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-ct024","article-title":"Abstract CT024: \u03b39\u03b42 T-cell (\u03b3\u03b4TC) activation and azacitidine-venetoclax (AV) for older\/unfit adults with newly diagnosed (ND) acute myeloid leukemia (AML) induces high rates of complete remission (CR): Preliminary efficacy, safety, pharmacodynamics (PD) and dose selection of ICT01 in the phase 1 study EVICTION","volume":"85","author":"Maiti","year":"2025","journal-title":"Cancer Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-14-0467","article-title":"Recruitment of oligoclonal viral-specific T cells to kill human tumor cells using single-chain antibody-peptide-HLA fusion molecules","volume":"14","author":"Noy","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-7321","article-title":"Abstract 7321: A novel gamma-delta T cell engager platform for cancer immunotherapy","volume":"85","author":"Ding","year":"2025","journal-title":"Cancer Res"},{"key":"B158","article-title":"Takeda to acquire Adaptate Biotherapeutics to develop novel gamma delta (\u03b3\u03b4) T cell engager therapies targeting solid tumors [Press Release","volume-title":"Takeda","year":"2022"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-1618","article-title":"Abstract 1618: A novel pan-gamma-delta T cell engager platform for next-generation cancer therapeutics","volume":"86","author":"Yang","year":"2026","journal-title":"Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-3517","article-title":"Abstract 3517: A bispecific pan-\u03b3\u03b4T cell engager with IL-15 fusion that activates both \u03b41 and \u03b42 types of \u03b3\u03b4T cells for the treatment of acute myeloid leukemia","volume":"85","author":"Yu","year":"2025","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.51","article-title":"MAIT cells: New guardians of the liver","volume":"5","author":"Kurioka","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-2121","article-title":"Abstract 2121: MAIT engagers: Providing a large therapeutic window for the treatment of solid tumors","volume":"85","author":"Plyte","year":"2025","journal-title":"Cancer Res"},{"key":"B163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2023.01.006","article-title":"The redirected killing of PD-L1 positive tumor cells by the expanded mucosa-associated invariant T (MAIT) cells is mediated with a bispecific antibody targeting TCR Valpha7.2 and PD-L1","volume":"644","author":"Yang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2024-6704","article-title":"Abstract 6704: Development and characterization of a tri-specific selective CD8 T cell engager (CD8xCD3xCD19) for treatment of B cell lymphoma","volume":"84","author":"Yang","year":"2024","journal-title":"Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240499","article-title":"CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease","volume":"221","author":"Michaelson","year":"2024","journal-title":"J Exp Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.01.020","article-title":"B-cell maturation antigen-targeted T-cell engager therapy combined with B-cell depletion for treatment of refractory HLA sensitization","volume":"109","author":"Leon","year":"2026","journal-title":"Kidney Int"},{"key":"B168","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s42003-023-04955-3","article-title":"A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo","volume":"6","author":"Li","year":"2023","journal-title":"Commun Biol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady2092","article-title":"Bispecific antibodies cross-link and redirect CD8(+) T cells to kill cytomegalovirus-infected cells","volume":"11","author":"Ali","year":"2025","journal-title":"Sci Adv"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.02.016","article-title":"Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection","volume":"141","author":"Pendzialek","year":"2017","journal-title":"Antiviral Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.omtm.2017.08.006","article-title":"In situ liver expression of HBsAg\/CD3-bispecific antibodies for HBV immunotherapy","volume":"7","author":"Kruse","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B172","unstructured":"Hepatogastroenterology [Internet]: Hep\n          \n          \n            \n              Highleyman\n              L\n            \n          \n          \n          2025"},{"key":"B173","unstructured":"Drugs@Fda: Fda-Approved Drugs\n          \n          \n          \n          2025"},{"key":"B174","first-page":"1","article-title":"LYNOZYFIC full prescribing information","volume-title":"Us.Lyn.24.04.0007.","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:52:45Z","timestamp":1784699565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1885909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":174,"alternative-id":["10.3389\/fimmu.2026.1885909"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1885909","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1885909"}}